NCT03736369 - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3) | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

August 7, 2019

Study Completion Date

August 7, 2019

Conditions

Erosive Esophagitis

Interventions

DRUG

DWP14012 40mg

DWP14012 40mg, tablet, orally, once daily for up to 8 weeks

DRUG

DWP14012 40mg placebo

DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

DRUG

Esomeprazole 40mg

Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks

DRUG

Esomeprazole 40mg placebo

Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

Trial Locations (1)

Hanyang University Medical Center, Seoul